Immatics NV (IMTX)

[FACT-MASTER]

Well thank you for sharing that interesting article. I note that it references IMA402 which is Immatics proprietary targeting prame.

https://www.boerse-online.de/nachrichten/aktien/geheimtipp-diese-voellig-unbekannte-biotech-aktie-aus-deutschland-hat-niemand-auf-dem-schirm-20352622.html

Insider tip? Nobody has this completely unknown biotech stock from Germany on their radar

Along with BioNTech and other pharmaceutical companies, the shares of this German company are a hot candidate for a big price jump in 2024.

More than just BioNTech. Anyone looking for German biotech stocks will quickly end up with the Mainz stocks. There are other promising stocks that speculative investors should at least keep an eye on. For example, there is Immatics from Tübingen. The company focuses on the development and production of T cell-based immunotherapies for the treatment of cancer. What sounds complicated is essentially aimed at modifying T cells and then developing an immunotherapy that selectively and effectively attacks a patient's tumors.

The research on this takes place at three locations: Tübingen, Texas and Munich. The group also works with some well-known biotech giants such as Bristol-Myers-Squibb, Genmab and Moderna, who actively promote research. With more than 500 million US dollars, Immatics has enough financial resources to carry out clinical studies on the various active ingredients. 2024 could be a particularly exciting year for investors.

Will 2024 boost Immatics shares?
“We are working intensively to make IMA402 available to a broad patient population as quickly as possible and look forward to publishing the first clinical data in 2024,” the company announced last year. And the active ingredient for the treatment of cancer called IMA402 is not the only drug about which there could be news this year. There will also be new data for the active ingredient IMA-203 this year. In total, the Germans are currently preparing eleven treatments or are already in the first clinical study phases.

The year could have some surprises in store for the stock. The fact that the stock reacts to even small results was shown last year when the price shot up by 30 percent in one day after the publication of some clinical data.

That's what the analysts say
The stock is currently not receiving much attention from analysts on Wall Street. A current analysis by Mizuho Securities still believes the stock will have a medium-term price increase of over 13 percent. Two other analyzes at the end of last year were significantly higher. Leerink Partners even believed the stock had 86.69 upside potential and Chardan Capital had an incredible 103 percent.

According to data from the MarketScreener platform, six analysts currently recommend buying the stock. The average price potential is almost 60 percent. Risk-taking investors should therefore not lose sight of the stock this year.